CD36 expression in peripheral blood mononuclear cells reflects the onset of atherosclerosis

Burak Yazgan1, Erdi Sozen1, Betul Karademir1

  • 1Department of Biochemistry, Faculty of Medicine, Genetic and Metabolic Diseases Research Center (GEMHAM), Marmara University, Maltepe, Istanbul, 34854, Turkey.

Insights

Increased serum cholesterol drives atherosclerosis by promoting foam cell formation via CD36. This study shows CD36 mRNA in blood cells mirrors aortic CD36 levels, suggesting it as a biomarker for atherosclerosis burden.

Area of Science:

  • Biochemistry
  • Cardiovascular Biology
  • Molecular Biology

Background:

  • Atherosclerosis is a complex disease influenced by genetics and environment.
  • Elevated cholesterol and oxidized low-density lipoprotein (ox-LDL) are key triggers.
  • CD36 receptor-mediated ox-LDL uptake by mononuclear cells is crucial for foam cell formation and atherogenesis.

Purpose of the Study:

  • To investigate if CD36 expression in peripheral blood mononuclear cells (PBMCs) reflects aortic tissue levels in hypercholesterolemia.
  • To establish PBMCs as a potential biomarker for atherosclerotic burden.

Main Methods:

  • Immunohistochemistry of aortic specimens in hypercholesterolemic animal models.
  • Analysis of CD36, HNE-protein adducts, smooth muscle actin, and vimentin expression.
  • RT-PCR to determine CD36 mRNA expression in PBMCs and aorta of rabbits and humans.

Main Results:

  • Hypercholesterolemia significantly increased CD36 protein and related markers (HNE-protein adducts, smooth muscle actin, vimentin) in the aorta.
  • High cholesterol diet induced CD36 mRNA expression in both rabbit aorta and PBMCs.
  • A positive correlation was found between aortic and PBMC CD36 expression.
  • Human PBMCs from hypercholesterolemic individuals showed significantly higher CD36 mRNA levels than normocholesterolemic individuals.

Conclusions:

  • CD36 mRNA levels in PBMCs can serve as a reliable indicator of CD36 expression in aortic tissue.
  • PBMC CD36 mRNA levels show potential as a non-invasive biomarker for diagnosing atherosclerotic burden.

Related Concept Videos

Inflammation01:38

Inflammation

Overview
62.8K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
471
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
629
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
810